Hepatitis viruses

Denis M Dwyre, Paul V. Holland

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Citations (Scopus)

Abstract

Transmission of hepatitis through blood transfusion was first reported in 1943 (Beeson, 1943; Morgan and Williamson, 1943). Hepatitis transmitted through faecal-oral mechanisms was termed hepatitis A ‘epidemic hepatitis’, while hepatitis transmitted through blood and its derivatives ‘serum hepatitis’) was termed hepatitis B. These terms were formally adopted by the World Health Organization in the 1970s (Dienstag, 2002). Prevention of the transmission of hepatitis by blood transfusions began with donor screening through the use of a donor questionnaire, primarily for a history of hepatitis, commonly referred to as ‘yellow jaundice’. Laboratory screening for hepatitis B virus began in 1969, with the testing of blood donors for what eventually became known as the hepatitis B surface antigen (HBsAg). Soon after regular testing of donor blood for HBsAg was initiated and tests for antibody to the hepatitis A virus became available, it became apparent that the majority of cases of transfusion-transmitted viral hepatitis were not related to hepatitis A or hepatitis B. The then undefined virus, named non-A, non-B (NANB) hepatitis virus, was believed to be the cause of a large number of transfusion-related infections. In an effort to reduce the number of transfusion-transmitted NANB viral hepatitis infections, ‘surrogate’ or substitute testing of donor blood was evaluated in the 1970s, initially in the USA. In 1981, an association between elevated serum levels of alanine aminotransferase (ALT) in blood donors and transfusion-transmitted NANB hepatitis in recipients was reported (Aach et al., 1981; Alter et al., 1981).

Original languageEnglish (US)
Title of host publicationTransfusion Microbiology
PublisherCambridge University Press
Pages9-24
Number of pages16
ISBN (Print)9780511545245, 9780521453936
DOIs
StatePublished - Jan 1 2008

Fingerprint

Hepatitis Viruses
Hepatitis
Blood Donors
Blood Transfusion
Hepatitis A
Hepatitis B Surface Antigens
Hepatitis B
Hepatitis A Antibodies
Donor Selection
Virus Diseases
Jaundice
Serum
Alanine Transaminase
Hepatitis B virus
Tissue Donors
Viruses

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dwyre, D. M., & Holland, P. V. (2008). Hepatitis viruses. In Transfusion Microbiology (pp. 9-24). Cambridge University Press. https://doi.org/10.1017/CBO9780511545245.005

Hepatitis viruses. / Dwyre, Denis M; Holland, Paul V.

Transfusion Microbiology. Cambridge University Press, 2008. p. 9-24.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dwyre, DM & Holland, PV 2008, Hepatitis viruses. in Transfusion Microbiology. Cambridge University Press, pp. 9-24. https://doi.org/10.1017/CBO9780511545245.005
Dwyre DM, Holland PV. Hepatitis viruses. In Transfusion Microbiology. Cambridge University Press. 2008. p. 9-24 https://doi.org/10.1017/CBO9780511545245.005
Dwyre, Denis M ; Holland, Paul V. / Hepatitis viruses. Transfusion Microbiology. Cambridge University Press, 2008. pp. 9-24
@inbook{00947d94336b4251bb6cb2bc564de93a,
title = "Hepatitis viruses",
abstract = "Transmission of hepatitis through blood transfusion was first reported in 1943 (Beeson, 1943; Morgan and Williamson, 1943). Hepatitis transmitted through faecal-oral mechanisms was termed hepatitis A ‘epidemic hepatitis’, while hepatitis transmitted through blood and its derivatives ‘serum hepatitis’) was termed hepatitis B. These terms were formally adopted by the World Health Organization in the 1970s (Dienstag, 2002). Prevention of the transmission of hepatitis by blood transfusions began with donor screening through the use of a donor questionnaire, primarily for a history of hepatitis, commonly referred to as ‘yellow jaundice’. Laboratory screening for hepatitis B virus began in 1969, with the testing of blood donors for what eventually became known as the hepatitis B surface antigen (HBsAg). Soon after regular testing of donor blood for HBsAg was initiated and tests for antibody to the hepatitis A virus became available, it became apparent that the majority of cases of transfusion-transmitted viral hepatitis were not related to hepatitis A or hepatitis B. The then undefined virus, named non-A, non-B (NANB) hepatitis virus, was believed to be the cause of a large number of transfusion-related infections. In an effort to reduce the number of transfusion-transmitted NANB viral hepatitis infections, ‘surrogate’ or substitute testing of donor blood was evaluated in the 1970s, initially in the USA. In 1981, an association between elevated serum levels of alanine aminotransferase (ALT) in blood donors and transfusion-transmitted NANB hepatitis in recipients was reported (Aach et al., 1981; Alter et al., 1981).",
author = "Dwyre, {Denis M} and Holland, {Paul V.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1017/CBO9780511545245.005",
language = "English (US)",
isbn = "9780511545245",
pages = "9--24",
booktitle = "Transfusion Microbiology",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Hepatitis viruses

AU - Dwyre, Denis M

AU - Holland, Paul V.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Transmission of hepatitis through blood transfusion was first reported in 1943 (Beeson, 1943; Morgan and Williamson, 1943). Hepatitis transmitted through faecal-oral mechanisms was termed hepatitis A ‘epidemic hepatitis’, while hepatitis transmitted through blood and its derivatives ‘serum hepatitis’) was termed hepatitis B. These terms were formally adopted by the World Health Organization in the 1970s (Dienstag, 2002). Prevention of the transmission of hepatitis by blood transfusions began with donor screening through the use of a donor questionnaire, primarily for a history of hepatitis, commonly referred to as ‘yellow jaundice’. Laboratory screening for hepatitis B virus began in 1969, with the testing of blood donors for what eventually became known as the hepatitis B surface antigen (HBsAg). Soon after regular testing of donor blood for HBsAg was initiated and tests for antibody to the hepatitis A virus became available, it became apparent that the majority of cases of transfusion-transmitted viral hepatitis were not related to hepatitis A or hepatitis B. The then undefined virus, named non-A, non-B (NANB) hepatitis virus, was believed to be the cause of a large number of transfusion-related infections. In an effort to reduce the number of transfusion-transmitted NANB viral hepatitis infections, ‘surrogate’ or substitute testing of donor blood was evaluated in the 1970s, initially in the USA. In 1981, an association between elevated serum levels of alanine aminotransferase (ALT) in blood donors and transfusion-transmitted NANB hepatitis in recipients was reported (Aach et al., 1981; Alter et al., 1981).

AB - Transmission of hepatitis through blood transfusion was first reported in 1943 (Beeson, 1943; Morgan and Williamson, 1943). Hepatitis transmitted through faecal-oral mechanisms was termed hepatitis A ‘epidemic hepatitis’, while hepatitis transmitted through blood and its derivatives ‘serum hepatitis’) was termed hepatitis B. These terms were formally adopted by the World Health Organization in the 1970s (Dienstag, 2002). Prevention of the transmission of hepatitis by blood transfusions began with donor screening through the use of a donor questionnaire, primarily for a history of hepatitis, commonly referred to as ‘yellow jaundice’. Laboratory screening for hepatitis B virus began in 1969, with the testing of blood donors for what eventually became known as the hepatitis B surface antigen (HBsAg). Soon after regular testing of donor blood for HBsAg was initiated and tests for antibody to the hepatitis A virus became available, it became apparent that the majority of cases of transfusion-transmitted viral hepatitis were not related to hepatitis A or hepatitis B. The then undefined virus, named non-A, non-B (NANB) hepatitis virus, was believed to be the cause of a large number of transfusion-related infections. In an effort to reduce the number of transfusion-transmitted NANB viral hepatitis infections, ‘surrogate’ or substitute testing of donor blood was evaluated in the 1970s, initially in the USA. In 1981, an association between elevated serum levels of alanine aminotransferase (ALT) in blood donors and transfusion-transmitted NANB hepatitis in recipients was reported (Aach et al., 1981; Alter et al., 1981).

UR - http://www.scopus.com/inward/record.url?scp=84926105341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926105341&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511545245.005

DO - 10.1017/CBO9780511545245.005

M3 - Chapter

AN - SCOPUS:84926105341

SN - 9780511545245

SN - 9780521453936

SP - 9

EP - 24

BT - Transfusion Microbiology

PB - Cambridge University Press

ER -